disulfiram has been researched along with Malignant Melanoma in 12 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The alcohol-abuse deterrent disulfiram (DSF) is shown to have a highly selective toxicity against melanoma in culture, inducing a largely apoptotic response, with much lower toxicity against several other cell lines." | 7.72 | Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. ( Brayton, D; Cen, D; Farmer, PJ; Meyskens, FL; Shahandeh, B, 2004) |
| "Disulfiram (DSF) was identified using a drug screen as one of the several compounds that preferentially decreased proliferation in multiple melanoma subtypes compared with benign melanocytes." | 5.36 | Disulfiram induces copper-dependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma. ( Doudican, NA; Morrison, BW; Orlow, SJ; Patel, KR, 2010) |
| "Melanoma is highly resistant to conventional chemotherapy." | 5.31 | Disulfiram induces apoptosis in human melanoma cells: a redox-related process. ( Buckmeier, JA; Cen, D; Gonzalez, RI; Kahlon, RS; Meyskens, FL; Tohidian, NB, 2002) |
| "To investigate: a) whether sub-toxic DSF efficacy can be increased without Cu overload against human melanoma cells with unequal BRAF(V600E) mutant status and Her2-overexpressing SKBR3 breast cancer cells, by increasing H2O2 from exogenous SOD; b) to compare the anti-tumor efficacy of DSF with that of another clinically used copper chelator, tetrathiomolybdate (TTM)." | 3.81 | Disulfiram anti-cancer efficacy without copper overload is enhanced by extracellular H2O2 generation: antagonism by tetrathiomolybdate. ( Calderon-Aparicio, A; Rieber, M; Strasberg-Rieber, M, 2015) |
| "Experimental studies have indicated that disulfiram (Antabuse) has antineoplastic effects against melanoma, breast, and prostate cancer." | 3.80 | Use of disulfiram and risk of cancer: a population-based case-control study. ( Askgaard, G; Friis, S; Hallas, J; Pottegård, A; Thygesen, LC, 2014) |
| "The alcohol-abuse deterrent disulfiram (DSF) is shown to have a highly selective toxicity against melanoma in culture, inducing a largely apoptotic response, with much lower toxicity against several other cell lines." | 3.72 | Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. ( Brayton, D; Cen, D; Farmer, PJ; Meyskens, FL; Shahandeh, B, 2004) |
| "Melanoma is a malignancy of the skin that is resistant to conventional treatment, necessitating the development of effective and safe new therapies." | 1.91 | Subcutaneous Rapid Dissolution Microneedle Patch Integrated with CuO ( Cai, Y; Feng, J; Ni, H; Xu, X; Yu, S; Zhang, J, 2023) |
| "Disulfiram (DSF) was identified using a drug screen as one of the several compounds that preferentially decreased proliferation in multiple melanoma subtypes compared with benign melanocytes." | 1.36 | Disulfiram induces copper-dependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma. ( Doudican, NA; Morrison, BW; Orlow, SJ; Patel, KR, 2010) |
| "Melanoma is highly resistant to conventional chemotherapy." | 1.31 | Disulfiram induces apoptosis in human melanoma cells: a redox-related process. ( Buckmeier, JA; Cen, D; Gonzalez, RI; Kahlon, RS; Meyskens, FL; Tohidian, NB, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Li, C | 1 |
| Zhou, S | 1 |
| Chen, C | 1 |
| Zhu, L | 1 |
| Li, S | 1 |
| Song, Z | 1 |
| Liang, J | 1 |
| Tang, C | 1 |
| Xu, N | 1 |
| Liu, T | 1 |
| Liu, S | 1 |
| Yu, S | 1 |
| Ni, H | 1 |
| Xu, X | 1 |
| Cai, Y | 1 |
| Feng, J | 1 |
| Zhang, J | 1 |
| Askgaard, G | 1 |
| Friis, S | 1 |
| Hallas, J | 1 |
| Thygesen, LC | 1 |
| Pottegård, A | 1 |
| Cavalier, MC | 1 |
| Pierce, AD | 1 |
| Wilder, PT | 1 |
| Alasady, MJ | 1 |
| Hartman, KG | 1 |
| Neau, DB | 1 |
| Foley, TL | 1 |
| Jadhav, A | 1 |
| Maloney, DJ | 1 |
| Simeonov, A | 1 |
| Toth, EA | 1 |
| Weber, DJ | 1 |
| Calderon-Aparicio, A | 1 |
| Strasberg-Rieber, M | 1 |
| Rieber, M | 1 |
| Fernandez Del Ama, L | 1 |
| Jones, M | 1 |
| Walker, P | 1 |
| Chapman, A | 1 |
| Braun, JA | 1 |
| Mohr, J | 1 |
| Hurlstone, AF | 1 |
| Morrison, BW | 1 |
| Doudican, NA | 1 |
| Patel, KR | 1 |
| Orlow, SJ | 1 |
| Trapp, V | 1 |
| Lee, K | 1 |
| Doñate, F | 1 |
| Mazar, AP | 1 |
| Fruehauf, JP | 1 |
| Cen, D | 2 |
| Gonzalez, RI | 1 |
| Buckmeier, JA | 1 |
| Kahlon, RS | 1 |
| Tohidian, NB | 1 |
| Meyskens, FL | 2 |
| Brar, SS | 1 |
| Grigg, C | 1 |
| Wilson, KS | 1 |
| Holder, WD | 1 |
| Dreau, D | 1 |
| Austin, C | 1 |
| Foster, M | 1 |
| Ghio, AJ | 1 |
| Whorton, AR | 1 |
| Stowell, GW | 1 |
| Whittall, LB | 1 |
| Whittle, RR | 1 |
| White, DP | 1 |
| Kennedy, TP | 1 |
| Brayton, D | 1 |
| Shahandeh, B | 1 |
| Farmer, PJ | 1 |
| Thibaut, S | 1 |
| Bourré, L | 1 |
| Hernot, D | 1 |
| Rousset, N | 1 |
| Lajat, Y | 1 |
| Patrice, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Open Labeled Trial of Disulfiram With Copper in Metastatic Breast Cancer[NCT03323346] | Phase 2 | 150 participants (Anticipated) | Interventional | 2017-09-29 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 other studies available for disulfiram and Malignant Melanoma
| Article | Year |
|---|---|
DDTC-Cu(I) based metal-organic framework (MOF) for targeted melanoma therapy by inducing SLC7A11/GPX4-mediated ferroptosis.
Topics: Alcoholism; Amino Acid Transport System y+; Animals; Cell Line, Tumor; Copper; Disulfiram; Ditiocarb | 2023 |
Subcutaneous Rapid Dissolution Microneedle Patch Integrated with CuO
Topics: Disulfiram; Humans; Hydrogen Peroxide; Melanoma; Micelles; Photothermal Therapy; Povidone | 2023 |
Use of disulfiram and risk of cancer: a population-based case-control study.
Topics: Aged; Alcohol Deterrents; Breast Neoplasms; Case-Control Studies; Denmark; Disulfiram; Female; Human | 2014 |
Covalent small molecule inhibitors of Ca(2+)-bound S100B.
Topics: Animals; Benzophenanthridines; Benzoquinones; Binding Sites; Calcium; Cations, Divalent; Cattle; Cel | 2014 |
Disulfiram anti-cancer efficacy without copper overload is enhanced by extracellular H2O2 generation: antagonism by tetrathiomolybdate.
Topics: Acetylcysteine; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell S | 2015 |
Reprofiling using a zebrafish melanoma model reveals drugs cooperating with targeted therapeutics.
Topics: Abietanes; Animals; Animals, Genetically Modified; Apoptosis; Benzamides; Cell Line, Tumor; Disease | 2016 |
Disulfiram induces copper-dependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma.
Topics: Apoptosis; Cell Growth Processes; Cell Line, Tumor; Copper; Copper Sulfate; Disulfiram; Humans; Mela | 2010 |
Redox-related antimelanoma activity of ATN-224.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Line, T | 2009 |
Disulfiram induces apoptosis in human melanoma cells: a redox-related process.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Buthionine Sulfoximine; Cell Division; Disulfiram; Enzym | 2002 |
Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Copper; Cyclic AMP Response El | 2004 |
Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells.
Topics: Apoptosis; Cell Line, Tumor; Copper; Disulfiram; Humans; Melanoma; Phenanthrolines | 2004 |
Effects of BAPTA-AM, Forskolin, DSF and Z.VAD.fmk on PDT-induced apoptosis and m-THPC phototoxicity on B16 cells.
Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Cell Survival; Chelating Agents; Colforsin; Cys | 2002 |